Jounce Therapeutics Story

Requested story not found. it has been either deleted or moved. View all stories for Jounce Therapeutics.

Jounce Therapeutics Latest Timeline

Jounce Therapeutics is listed for 1.88. About 16.0% of the company shares are held by company insiders. The company has price-to-book ratio of 0.27. Some equities with similar Price to Book (P/B) outperform the market in the long run. Jounce Therapeutics recorded a loss per share of 0.96. The entity had not issued any dividends in recent years.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Jounce Therapeutics information on this page should be used as a complementary analysis to other Jounce Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.